Abstract
Antimicrobials have undoubtedly improved the lives of people with CF, but important antimicrobial-related toxicities and the emergence of antimicrobial-resistant bacteria associated with their use must be considered. Antimicrobial stewardship (AMS) is advocated across the spectrum of healthcare to promote the appropriate use of antimicrobials to preserve their current effectiveness and to optimise treatment, and it is clear that AMS strategies are applicable to and can benefit both non-CF and CF populations. This perspective explores the definition and components of an AMS program, the current evidence for AMS, and the reasons why AMS is a challenging concept in the provision of CF care. We also discuss the elements of CF care which align with AMS programs and principles and propose research priorities for AMS in CF.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 511-520 |
| Number of pages | 10 |
| Journal | Journal of Cystic Fibrosis |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jul 2020 |
Keywords
- Antimicrobial stewardship
- Antimicrobials
- Pulmonary Exacerbations
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'Finding the relevance of antimicrobial stewardship for cystic fibrosis'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Finding the relevance of antimicrobial stewardship for cystic fibrosis. / Antimicrobial Resistance International Working Group in Cystic Fibrosis.
In: Journal of Cystic Fibrosis, Vol. 19, No. 4, 07.2020, p. 511-520.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Finding the relevance of antimicrobial stewardship for cystic fibrosis
AU - Antimicrobial Resistance International Working Group in Cystic Fibrosis
AU - Cogen, Jonathan D.
AU - Kahl, Barbara C.
AU - Maples, Holly
AU - McColley, Susanna A.
AU - Roberts, Jason A.
AU - Winthrop, Kevin L.
AU - Morris, Andrew M.
AU - Holmes, Alison
AU - Flume, Patrick A.
AU - VanDevanter, Donald R.
AU - Waters, Valerie
AU - Muhlebach, Marianne S.
AU - Elborn, J. Stuart
AU - Saiman, Lisa
AU - Bell, Scott C.
N1 - Funding Information: This work was funded by the European Cystic Fibrosis Society , Cystic Fibrosis Foundation , Cystic Fibrosis Trust , Cystic Fibrosis Canada , and Cystic Fibrosis Australia . Jonathan Cogen has funding from the CF Foundation (USA). Susanna McColley is supported, in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Number UL1TR001422 . Jason Roberts has funding from the Australian National Health and Medical Research Council for Centre of Research Excellence and Practitioner Fellowship. Alison Holmes is a National Institute for Health Research (NIHR) Senior Investigator. She also acknowledges the support of the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London. Patrick Flume is supported, in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Number UL1TR001450 . J. Stuart Elborn receives funding from the Innovative Medicines Initiative , Framework Seven, European Commission and from the Medical Research Council, UK . Lisa Saiman receives funding from the CF Foundation (USA). Scott Bell has funding from Australian National Health and Medical Research Council , the CF Foundation (USA) and the Queensland Children's Foundation . Funding Information: This work was funded by the European Cystic Fibrosis Society, Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Cystic Fibrosis Canada, and Cystic Fibrosis Australia. Jonathan Cogen has funding from the CF Foundation (USA). Susanna McColley is supported, in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Number UL1TR001422. Jason Roberts has funding from the Australian National Health and Medical Research Council for Centre of Research Excellence and Practitioner Fellowship. Alison Holmes is a National Institute for Health Research (NIHR) Senior Investigator. She also acknowledges the support of the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Imperial College London. Patrick Flume is supported, in part, by the National Center for Advancing Translational Sciences of the National Institutes of Health under Grant Number UL1TR001450. J. Stuart Elborn receives funding from the Innovative Medicines Initiative, Framework Seven, European Commission and from the Medical Research Council, UK. Lisa Saiman receives funding from the CF Foundation (USA). Scott Bell has funding from Australian National Health and Medical Research Council, the CF Foundation (USA) and the Queensland Children's Foundation.This work was funded by the European Cystic Fibrosis Society, Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Cystic Fibrosis Canada, and Cystic Fibrosis Australia. We are grateful to Christine Dubois for managing the coordination of the Antimicrobial Resistance International Working Group in Cystic Fibrosis and Mary Philips, Metro North Hospital and Health Service for her illustration skills. Funding Information: Drs. Kahl, Maples, Holmes and Muhlebach have nothing to disclose. Dr. Cogen reports grants from the Cystic Fibrosis Foundation outside of this work. Dr. McColley reports disclosures from Vertex Pharmaceuticals, Gilead Sciences, and grants from Northwestern University Clinical and Translational Sciences Institute outside of this work. Dr. Roberts reports grants and personal fees from MSD, grants from QPEX, personal fees from Discuva, personal fees from Accelerate Diagnostics, grants and personal fees from Biomerieux, grants and personal fees from Pfizer and grants from The Medicines Company outside of this work. Dr. Winthrop reports grants and personal fees from Pfizer, personal fees from AbbVie, personal fees from UCB, personal fees from Lilly, personal fees from Galapagos, personal fees from GSK, personal fees from Roche, personal fees from Gilead, grants from BMS, and grants from Insmed outside of this work. Dr. Morris reports and receives salary support from the Sinai Health and University Health Network in his role as Director of their Antimicrobial Stewardship Program. Dr. Flume reports grants outside of this submitted work from the European Cystic Fibrosis Society, the Cystic Fibrosis Foundation, Cystic Fibrosis Trust, Cystic Fibrosis Canada, Cystic Fibrosis Australia, and Novoteris. Dr. Flume also receives personal fees from Insmed outside this submitted work. Dr. VanDevanter reports personal fees from AbbVie, Albumedix, AN2, Aradigm, Armata, Arrevus, Calithera, Chiesi USA, Cipla, Corbus, Cystic Fibrosis Foundation, Eloxx, Enbiotix, Eveo, Galephar, Horizon, IBF, ICON clinical sciences, Ionis, Kala, Merck, Microbion, NDA, Protalix, PTC, Pulmocide, Recida, Savara, Vast, and Vertex outside of this work. Dr. Waters reports grants from Gilead and Astrazenca outside of this work. Dr. Elborn reports grants from Innovative Medicines Institute, Framework Seven, European Commission, Medical Research Council, and Bronch UK during the conduct of the study. Dr. Saiman reports grants from the CF Foundation, Merck, and AztraZeneca outside of this work. Dr. Bell reports grants and other support from Vertex, Galapagos and AbbVie outside of this work. Publisher Copyright: © 2020
PY - 2020/7
Y1 - 2020/7
N2 - Antimicrobials have undoubtedly improved the lives of people with CF, but important antimicrobial-related toxicities and the emergence of antimicrobial-resistant bacteria associated with their use must be considered. Antimicrobial stewardship (AMS) is advocated across the spectrum of healthcare to promote the appropriate use of antimicrobials to preserve their current effectiveness and to optimise treatment, and it is clear that AMS strategies are applicable to and can benefit both non-CF and CF populations. This perspective explores the definition and components of an AMS program, the current evidence for AMS, and the reasons why AMS is a challenging concept in the provision of CF care. We also discuss the elements of CF care which align with AMS programs and principles and propose research priorities for AMS in CF.
AB - Antimicrobials have undoubtedly improved the lives of people with CF, but important antimicrobial-related toxicities and the emergence of antimicrobial-resistant bacteria associated with their use must be considered. Antimicrobial stewardship (AMS) is advocated across the spectrum of healthcare to promote the appropriate use of antimicrobials to preserve their current effectiveness and to optimise treatment, and it is clear that AMS strategies are applicable to and can benefit both non-CF and CF populations. This perspective explores the definition and components of an AMS program, the current evidence for AMS, and the reasons why AMS is a challenging concept in the provision of CF care. We also discuss the elements of CF care which align with AMS programs and principles and propose research priorities for AMS in CF.
KW - Antimicrobial stewardship
KW - Antimicrobials
KW - Pulmonary Exacerbations
UR - http://www.scopus.com/inward/record.url?scp=85080131977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080131977&partnerID=8YFLogxK
U2 - 10.1016/j.jcf.2020.02.012
DO - 10.1016/j.jcf.2020.02.012
M3 - Review article
C2 - 32122785
AN - SCOPUS:85080131977
VL - 19
SP - 511
EP - 520
JO - Journal of Cystic Fibrosis
JF - Journal of Cystic Fibrosis
SN - 1569-1993
IS - 4
ER -